Lumos Pharma, Inc. (LUMO) Misses Q1 EPS by 30c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q1 EPS of ($1.29), $0.30 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $303.25 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c